ROS-mediated increase in PGC-1a was associated with cisplatin resistance in NSCLC. PGC-1α interference or OXPHOS inhibition using metformin delayed or counteracted cisplatin resistance. This evidence concerns the gene PPARGC1A and non-small cell lung carcinoma.